article thumbnail

Five Years of Forbes | Legacy MEDSearch Ranks on the Forbes Best Executive Recruitment Firms for a Fifth Consecutive Year

Legacy MEDSearch

Leadership includes Joy Celebre (recruiting since 1996, joined in 2008), Carolyn Jones (recruiting since 1995, joined in 2011), Arshad Alam (recruiting since 1995, joined 2017), John White (Talent Sourcing Manager, joined 2012), and Partner Chris Miclot, (joined 2012). “In

article thumbnail

Anna Walz

Pharma Marketing Network

With Anna at the helm, MedEvoke has quickly become a leading partner to many top-20 pharmaceutical corporations. Anna was named a Top 100 PharmaVoice “most inspiring leader” in 2012.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lessons from the Top 100: Thales [Podcast]

Clarivate

Every year since 2012, Clarivate has identified the Top 100 Global Innovators. These companies and institutions lead the global innovation landscape, contributing new ideas, solving some of the world’s most complex challenges and creating new value. Listen to the podcast.

Leads 98
article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

Leading the MHRA – a five year journey Professor Graham Cooke, interim chair of the MHRA board, remarked that Dame June’s “leadership of the MHRA over the last five years, particularly during the COVID-19 pandemic, has been exceptional.”

article thumbnail

EC approves first-line ovarian cancer treatment

European Pharmaceutical Review

Thomas’ NHS Foundation Trust and King’s College London, London, UK, and European Network of Gynaecological Oncological Trial (ENGOT) lead of the ATHENA trial for rucaparib.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s 56% of RSAs have been established as arrangements in the UK The UK leads the total global number of RSAs made since 2012 (56%), many of which are simple, discount-based patient access schemes (PAS).

Marketing 105
article thumbnail

Shorter timelines, evolving strategies: Four key trends in regulatory approvals of new medicines

Clarivate

The following blog post summarizes key findings from the latest CIRS R&D Briefing, New drug approvals in six major authorities 2012-2021. The resulting analyses, published annually since 2012, give unique insights into regulatory processes and practices, identify where improvements can be made and inform company and agency strategies.